Biodexa Pharmaceuticals Adjusts Share Value Amid Drug Development Focus

Biodexa Pharmaceuticals (BDRX) has released an update.

Biodexa Pharmaceuticals has successfully passed resolutions at its General Meeting to reduce the nominal value per ordinary share, without affecting the number of shares outstanding. This move comes as the company continues to focus on developing innovative treatments for diseases with unmet medical needs, including its lead programs eRapa, tolimidone, and MTX110. Biodexa’s advancements in drug delivery technologies support its ambitious pipeline, potentially boosting investor interest in its growth prospects.

For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.